INFO:

What treatment strategy would you choose for a 45-year-old patient with hormone receptor–positive, HER2-negative, locally advanced early-stage breast cancer? Hope S. Rugo, MD, and Sara M. Tolaney, MD, MPH, discuss the “tricky” elements that must be considered when weighing difficult choices in this case.